doc_id,table_id,row_index,ColumnA,ColumnB,ColumnC,ColumnD,ColumnE,ColumnF
WHO_TB_handbook_module4_treatment_2025,Table 1.2.1.,1,Regimen,0-3 months,3 months-10 years,10-12 years,12-16 years,>16 years
WHO_TB_handbook_module4_treatment_2025,Table 1.2.1.,2,2HRZ(E)/4HR,Ethambutol should be added in settings with a high background prevalence of isoniazid resistance or HIV infection or in CLHIV,Ethambutol should be added in settings with a high background prevalence of isoniazid resistance or HIV infection or in CLHIV,Independent of disease severity or HIV status,Independent of disease severity or HIV status,Independent of disease severity or HIV status
WHO_TB_handbook_module4_treatment_2025,Table 1.2.1.,3,2HRZ(E)/2HR,,"Non-severe TB, > 3 kg, add ethambutol in settings with a high background prevalence of isoniazid resistance or HIV infection or in CALHIV","Non-severe TB, > 3 kg, add ethambutol in settings with a high background prevalence of isoniazid resistance or HIV infection or in CALHIV","Non-severe TB, > 3 kg, add ethambutol in settings with a high background prevalence of isoniazid resistance or HIV infection or in CALHIV",
WHO_TB_handbook_module4_treatment_2025,Table 1.2.1.,4,2HPMZ/2HPM,,,,Independent of disease severity or HIV status,Independent of disease severity or HIV status
WHO_TB_handbook_module4_treatment_2025,Table 1.2.1.,5,Additional factors to be considered if several regimens are possible,"Patient or family preference, Access and cost of regimen component drugs","Disease severity, Patient or family preference, Access and cost of regimen component drugs","Disease severity, Patient or family preference, Access and cost of regimen component drugs","Disease severity, Patient or family preference, Access and cost of regimen component drugs","Patient or family preference, Access and cost of regimen component drugs"